ERAS Erasca, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1761918 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-141.2%
TTM EPS YoY-125.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.7%
ROA-43.4%
ROIC (approx.)-48.1%
Asset turnover—
Leverage & solvency
Liabilities / assets8.2%
Debt / equity0.00x
Current ratio14.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-28.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $47.20M | $35.90M | $27.27M | $23.24M | $22.47M | $21.17M | $25.97M | $26.12M |
| SG&A expense | $12.33M | $11.72M | $10.65M | $9.36M | $10.07M | $9.46M | $9.66M | $9.59M |
| Operating income | -$59.52M | -$47.62M | -$187.91M | -$32.60M | -$34.55M | -$38.12M | -$35.63M | -$35.71M |
| Net income | -$51.33M | -$44.08M | -$183.44M | -$29.09M | -$30.61M | -$33.88M | -$30.97M | -$32.23M |
| EBITDA | -$58.81M | -$46.90M | -$187.19M | -$31.86M | -$33.79M | -$37.34M | -$34.81M | -$34.88M |
| EPS (basic) | -0.15 | -0.14 | -0.60 | — | -0.11 | -0.12 | -0.11 | — |
| EPS (diluted) | -0.15 | -0.14 | -0.60 | — | -0.11 | -0.12 | -0.11 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Weighted avg. shares (diluted) | 344.24M | 311.34M | 304.32M | — | 283.68M | 283.36M | 283.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $118.96M | $42.54M | $47.26M | $73.81M | $70.23M | $66.14M | $70.48M | $67.74M |
| Short-term investments | $524.74M | $226.20M | $196.53M | $202.27M | $218.17M | $234.52M | $234.10M | $230.57M |
| Current assets | $655.19M | $278.44M | $253.78M | $286.24M | $299.93M | $310.66M | $314.62M | $308.79M |
| PP&E, net | $11.33M | $11.92M | $12.61M | $13.30M | $14.04M | $14.82M | $15.59M | $16.32M |
| Total assets | $998.94M | $435.05M | $461.23M | $396.15M | $420.40M | $445.39M | $471.24M | $502.53M |
| Current liabilities | $43.99M | $33.57M | $26.66M | $28.51M | $28.71M | $28.15M | $25.47M | $31.39M |
| Total liabilities | $82.20M | $73.19M | $67.71M | $70.98M | $72.52M | $73.13M | $71.74M | $79.03M |
| Shareholders' equity | $916.74M | $361.87M | $393.53M | $325.17M | $347.89M | $372.26M | $399.50M | $423.50M |
| Shares outstanding | 350.24M | 312.56M | 310.81M | 284.16M | 283.71M | 283.65M | 283.27M | 283.22M |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.74M | -$27.27M | -$27.38M | -$21.71M | -$21.66M | -$20.53M | -$31.55M | -$24.56M |
| Capital expenditure | $79,000 | $8,000 | $36,000 | $9,000 | $6,000 | $30,000 | $83,000 | $0 |
| Free cash flow | -$32.82M | -$27.28M | -$27.42M | -$21.72M | -$21.66M | -$20.56M | -$31.64M | -$24.56M |
| Investing cash flow | -$488.34M | $19.49M | -$243.83M | $24.71M | $25.70M | $15.74M | $34.27M | $22.62M |
| Financing cash flow | $597.50M | $3.06M | $244.66M | $575,000 | $41,000 | $447,000 | $33,000 | $801,000 |
| Depreciation & amortization | $712,000 | $716,000 | $723,000 | $743,000 | $755,000 | $787,000 | $822,000 | $832,000 |
| Stock-based compensation | $11.93M | $9.61M | $8.46M | $5.82M | $5.96M | $6.40M | $6.71M | $6.31M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.